



INDO-BANGLA PHARMACEUTICALS LIMITED

PLOT # 183 (7th FLOOR), BLOCK # B, AHMED AKBER SOBHAN ROAD,
BASHUNDHARA R/A, Dhaka-1229.

PRICE SENSITIVE INFORMATION

This is for information of all concerned that the Board of Directors of Indo-Bangla Pharmaceuticals Ltd., in its Meeting held on 29th April 2021 at 2:00 p.m. at its Corporate Office, Plot # 183 (7th Floor), Block # B, Ahmed Akbar Sobhan Road, Bashundhara R/A, Dhaka-1229 and approved the Third Quarter (Q 3) Un-Audited Financial Statements for the period ended 31st March, 2021.

The key financial highlights for the Third Quarter (Q 3) ended 31th March 2021 are appended below:

SL No.	Particulars	9 months		3 months	
		July to March		January to March	
		2020-2021	2019-2020	2020-2021	2019-2020
1.	Earnings Per Share (EPS)	0.79	1.24	0.12	0.42
2.	Net Operating Cash Flows Per Share (NOCFPS)	0.84	1.29	-	-
		As at 31 st March, 2021		As at 30 th June, 2020	
3.	Net Asset Value (NAV) per share	13.89		13.61	

The reasons behind of sloping down Net Sales revenue and Earnings Per Share (EPS) are as follows:

- A. The weighted average number of ordinary shares outstanding for the quarter ended 31 March 2020 and 31 March 2021 is 111,507,000 and 113,737,140 respectively, so as to the one of the remarkable reasons including others behind of sloping down EPS is dropping turnover July 2020 to March, 2021 and January to March, 2021 by 11.58% and 23.47%. respectively.
- B. Reasons for shortfall in revenue that The Directorate General of Drug Administration (DGDA) issued a memo vide ref: DGDA/ML-032/06/4616 dated 7 March 2021 suspending the production and marketing of all licensed items and cancelling the registration of 8 (eight) articles temporarily of the company. So as from 7 March 2021 to 13 April 2021, the company have remained away from producing and selling of all licensed products and it turned down the business revenue substantially.
- C. The Directorate General of Drug Administration (DGDA) has withdrawn the temporary suspension order of production and marketing of all licensed items excluding 8 (eight) reputable selling products of the company that is triggering to turned down the business revenue.
- D. The company has broken fixed deposits into cash as a consequence of having no interest income in this quarter like last ones of previous year. In the quarter January to March, 2021 an amount of BDT 407,800 is shown as non-operating income which is derived from the sale of wastage. In the statement of financial position BDT 19,374,428 is shown as non-operating income which is derived from short-term investment in Fixed Deposit 9-month period ended 31 March, 2020, whereas in this 9-month period ended 31 March, 2021 the amount in short-term investment is shown at zero.

E. In addition, operating expenses have been increased in comparison to last quarter due to increased amount of administrative workforce salary, an increased amount of depreciation on newly acquired machineries and equipment, finance charge on borrowing, increase in salary and allowance of selling and distribution workforce. These unfavorable changes have resulted in decreased net profit by -36.31% for the Year to Year comparison and -70.02% for Quarter to Quarter comparison.

This is for your kind information and record.

By order of the Board of Directors

-sd-

(Mohi Uddin QCS)
Company Secretary

The details of the published Third Quarter (Q3) Financial Statements are available in the website of the company: www.indo-banglapharma.com.